Any current/future new fundraising through debt or equity?

Chandan Healthcare Limited has already raised funds through preferential shares amounting to INR104 crores. As of now, INR26 crores (25% of the preferential shares) has been received, with the balance expected within the next year. This fundraising is considered sufficient for the company's expansion plans over the next year. Management does not anticipate any further equity dilution or fundraising through equity for the next two to three years. There is no mention of any planned or ongoing debt fundraising in the provided content. Overall, the company is well-capitalized for near-te

Any current/future capex/capital investment/strategic investment?

Planned investment of INR 100 crores over the next three years for setting up 100 new laboratories. Each laboratory requires approximately INR 1 crore in capex (INR 50-75 lakhs for setup plus INR 50 lakhs for machines). Preferential shares of INR 104 crores have been raised, with INR 26 crores already received, to fund expansion smoothly. Expansion plan includes launching 13 new labs, 3 comprehensive centres, a PET scan facility at Gorakhpur, and a genome lab at Lucknow in the coming year. Central lab and wellness centre to begin in H1 FY27 at Jankipuram, Lucknow, expected to be the largest la

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth significantly higher than 30% in FY'27, surpassing previous projections. Expansion plans include government contracts worth INR55-52 crores annually (Punjab and Guwahati project), acting as a game changer. EBITDA margins are anticipated to improve quarter-on-quarter, with current diagnostic EBITDA margins already above 30%; aiming to increase overall margins to 35%+. EBITDA margins for B2C business are around 35-40%, considered sustainable, though consolidated margins average 30-35% due to B2B and B2G segments. Positive net cash inflow from operations is expe

IN US

Sale is live|00:00:00left today

Chandan Healthcare LtdQ4 FY27Healthcare Services

Chandan Healthcare Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹240P/E: 20.8Market Cap: ₹604 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 1

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

5 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 1

→Chandan Healthcare Limited expects top-line growth much higher than 30% in the next financial year (FY’27), surpassing current projections.
→New government contracts, including a INR55 crore per year project in Punjab and Guwahati, will act as significant growth drivers.
→Expansion plans include launching 18 new labs and 37 comprehensive centers in the current year, with further scale-up in the next two to three years.
→The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion.
→A strategic focus on Tier 2, 3, and 4 cities, which contribute 90% of the business, will support volume growth.
→Growth is supported by a robust team and preferential shares funding of INR104 crores, ensuring smooth expansion.
→Quarterly incremental growth is expected, with visible improvements in Q4 FY’27 and beyond.

Margin guidance

Category 1

→The company expects revenue growth significantly higher than 30% in FY'27, surpassing previous projections.
→Expansion plans include government contracts worth INR55-52 crores annually (Punjab and Guwahati project), acting as a game changer.
→EBITDA margins are anticipated to improve quarter-on-quarter, with current diagnostic EBITDA margins already above 30%; aiming to increase overall margins to 35%+.
→EBITDA margins for B2C business are around 35-40%, considered sustainable, though consolidated margins average 30-35% due to B2B and B2G segments.
→Positive net cash inflow from operations is expected with improving working capital.
→No further equity dilution is anticipated for capex over the next 2-3 years due to preferential shares funds already raised.
→PAT and bottom line are expected to reflect significant growth aligned with revenue and contract wins starting next year.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Chandan Healthcare Limited has already raised funds through preferential shares amounting to INR104 crores.
→As of now, INR26 crores (25% of the preferential shares) has been received, with the balance expected within the next year.
→This fundraising is considered sufficient for the company's expansion plans over the next year.
→Management does not anticipate any further equity dilution or fundraising through equity for the next two to three years.
→There is no mention of any planned or ongoing debt fundraising in the provided content.
→Overall, the company is well-capitalized for near-term expansion and does not foresee additional fundraising needs imminently.

Order book

Yes

- Chandan Healthcare Limited has secured significant government contracts, including a major contract from Punjab and Guwahati, valued at approximately INR 55 crores annually. - The company has a fully subscribed preferential shares issuance of INR 104 crores, of which INR 26 crores (25%) has been received, with the balance expected within the next year to fund expansion plans. - Expansion plans include launching 18 new labs and 7 comprehensive centers this year, with an additional 13 labs and 3 comprehensive centers planned next year. - New labs are starting soon in multiple cities: Mumbai, Kolkata, Chandigarh, Ahmedabad, Surat, Vadodara, Guwahati, Kurukshetra, and Kota. - The orderbook includes setting up a genome lab at Lucknow and a PET scan facility at Gorakhpur, along with wellness and central labs, particularly the largest central lab in Uttar Pradesh at Jankipuram, Lucknow. Overall, the order pipeline is robust and well-funded, supporting smooth expansion.

Capex plans

Yes

→Planned investment of INR 100 crores over the next three years for setting up 100 new laboratories.
→Each laboratory requires approximately INR 1 crore in capex (INR 50-75 lakhs for setup plus INR 50 lakhs for machines).
→Preferential shares of INR 104 crores have been raised, with INR 26 crores already received, to fund expansion smoothly.
→Expansion plan includes launching 13 new labs, 3 comprehensive centres, a PET scan facility at Gorakhpur, and a genome lab at Lucknow in the coming year.
→Central lab and wellness centre to begin in H1 FY27 at Jankipuram, Lucknow, expected to be the largest lab in Uttar Pradesh.
→The company is focusing on both owned labs (capex-heavy) and franchisee collection points (minimal capex).
→Expansion involves not only metropolitan cities but also Tier 2, 3, and 4 cities across 13 states.

How does Chandan Healthcare Ltd rank vs peers in Healthcare Services?

Pro feature

1Chandan Healthcare Ltd

Rev 1Mar 1

See full Healthcare Services sector rankings

Want more stocks like Chandan Healthcare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio